Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMEA To Get To Heart Of COX-2 Inhibitor Safety Issues At Feb. 14-17 Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

The Committee for Medicinal Products for Human Use requests further analyses from Pfizer, Merck and Novartis on the cardiovascular safety of COX-2 inhibitors. Pfizer agrees not to launch celecoxib for in an orphan polyp indication until after completion of EMEA's class safety review.

You may also be interested in...



Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007

Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.

Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007

Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.

COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda

FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel